Literature DB >> 18023943

Vaccine-induced protection from infection of mice by chimeric human immunodeficiency virus type 1, EcoHIV/NL4-3.

Manisha Saini1, Eran Hadas, David J Volsky, Mary Jane Potash.   

Abstract

EcoHIV/NL4-3 is a chimeric human immunodeficiency virus type 1 (HIV-1) that can productively infect mice. This study tests the utility of EcoHIV/NL4-3 infection to reveal protective immune responses to an HIV-1 vaccine. Immunocompetent mice were first immunized with VRC 4306 which encodes subtype B consensus sequences of gag, pol, and nef and then were infected by EcoHIV/NL4-3. Anti-Gag antibodies were sampled during immunization and infection. The extent of EcoHIV/NL4-3 infection in spleen cells and peritoneal macrophages was determined by quantitative real-time PCR (QPCR). Although antibody titres were not significantly different in control and vaccinated groups, VRC 4306 immunization induced protective responses that significantly reduced virus burden in both lymphocyte and macrophage compartments. These results indicate that EcoHIV/NL4-3 infection can be controlled by HIV-1 vaccine-induced responses, introducing a small animal model to test vaccine efficacy against HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18023943      PMCID: PMC2219693          DOI: 10.1016/j.vaccine.2007.10.019

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.

Authors:  D H Barouch; S Santra; J E Schmitz; M J Kuroda; T M Fu; W Wagner; M Bilska; A Craiu; X X Zheng; G R Krivulka; K Beaudry; M A Lifton; C E Nickerson; W L Trigona; K Punt; D C Freed; L Guan; S Dubey; D Casimiro; A Simon; M E Davies; M Chastain; T B Strom; R S Gelman; D C Montefiori; M G Lewis; E A Emini; J W Shiver; N L Letvin
Journal:  Science       Date:  2000-10-20       Impact factor: 47.728

Review 2.  Progress and obstacles in the development of an AIDS vaccine.

Authors:  Norman L Letvin
Journal:  Nat Rev Immunol       Date:  2006-12       Impact factor: 53.106

3.  Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model.

Authors:  Erik Rollman; Nathalie Mathy; Andreas Bråve; Andreas Boberg; Anne Kjerrström; Cathy van Wely; Gunnel Engström; Susanne Johansson; Kajsa Aperia; Lars E Eriksson; Reinhold Benthin; Peter Ertl; Jonathan Heeney; Jorma Hinkula; Gerald Voss; Britta Wahren
Journal:  Vaccine       Date:  2006-11-13       Impact factor: 3.641

4.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

Review 5.  A review of vaccine research and development: the human immunodeficiency virus (HIV).

Authors:  Marc P Girard; Saladin K Osmanov; Marie Paule Kieny
Journal:  Vaccine       Date:  2006-02-28       Impact factor: 3.641

6.  Testing antiretroviral drug efficacy in conventional mice infected with chimeric HIV-1.

Authors:  Eran Hadas; Alejandra Borjabad; Wei Chao; Manisha Saini; Kozi Ichiyama; Mary Jane Potash; David J Volsky
Journal:  AIDS       Date:  2007-05-11       Impact factor: 4.177

7.  Isolation of human T-lymphotropic retrovirus (LAV) from Zairian married couple, one with AIDS, one with prodromes.

Authors:  A Ellrodt; F Barre-Sinoussi; P Le Bras; M T Nugeyre; L Palazzo; F Rey; F Brun-Vezinet; C Rouzioux; P Segond; R Caquet
Journal:  Lancet       Date:  1984-06-23       Impact factor: 79.321

8.  Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi.

Authors:  S L Rowland-Jones; T Dong; K R Fowke; J Kimani; P Krausa; H Newell; T Blanchard; K Ariyoshi; J Oyugi; E Ngugi; J Bwayo; K S MacDonald; A J McMichael; F A Plummer
Journal:  J Clin Invest       Date:  1998-11-01       Impact factor: 14.808

9.  Immunogenicity of multiple gene and clade human immunodeficiency virus type 1 DNA vaccines.

Authors:  Wing-Pui Kong; Yue Huang; Zhi-Yong Yang; Bimal K Chakrabarti; Zoe Moodie; Gary J Nabel
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

Review 10.  HIV vaccines.

Authors:  Andrew J McMichael
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

View more
  15 in total

1.  Mice chronically infected with chimeric HIV resist peripheral and brain superinfection: a model of protective immunity to HIV.

Authors:  Jennifer L Kelschenbach; Manisha Saini; Eran Hadas; Chao-Jiang Gu; Wei Chao; Galina Bentsman; Jessie P Hong; Tomas Hanke; Leroy R Sharer; Mary Jane Potash; David J Volsky
Journal:  J Neuroimmune Pharmacol       Date:  2011-10-11       Impact factor: 4.147

2.  HIV infection model of chronic obstructive pulmonary disease in mice.

Authors:  Patrick Geraghty; Eran Hadas; Boe-Hyun Kim; Abdoulaye J Dabo; David J Volsky; Robert Foronjy
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-01-19       Impact factor: 5.464

3.  Multiple NF-κB sites in HIV-1 subtype C long terminal repeat confer superior magnitude of transcription and thereby the enhanced viral predominance.

Authors:  Mahesh Bachu; Swarupa Yalla; Mangaiarkarasi Asokan; Anjali Verma; Ujjwal Neogi; Shilpee Sharma; Rajesh V Murali; Anil Babu Mukthey; Raghavendra Bhatt; Snehajyoti Chatterjee; Roshan Elizabeth Rajan; Narayana Cheedarla; Venkat S Yadavalli; Anita Mahadevan; Susarla K Shankar; Nirmala Rajagopalan; Anita Shet; Shanmugam Saravanan; Pachamuthu Balakrishnan; Suniti Solomon; Madhu Vajpayee; Kadappa Shivappa Satish; Tapas K Kundu; Kuan-Teh Jeang; Udaykumar Ranga
Journal:  J Biol Chem       Date:  2012-11-06       Impact factor: 5.157

4.  Transmission of chimeric HIV by mating in conventional mice: prevention by pre-exposure antiretroviral therapy and reduced susceptibility during estrus.

Authors:  Eran Hadas; Wei Chao; Hongxia He; Manisha Saini; Eleen Daley; Mohammed Saifuddin; Galina Bentsman; Eric Ganz; David J Volsky; Mary Jane Potash
Journal:  Dis Model Mech       Date:  2013-07-25       Impact factor: 5.758

Review 5.  Tuberculosis and HIV co-infection.

Authors:  Andrzej Pawlowski; Marianne Jansson; Markus Sköld; Martin E Rottenberg; Gunilla Källenius
Journal:  PLoS Pathog       Date:  2012-02-16       Impact factor: 6.823

Review 6.  HIV-1 and drug abuse comorbidity: Lessons learned from the animal models of NeuroHIV.

Authors:  Susmita Sil; Annadurai Thangaraj; Ernest T Chivero; Fang Niu; Muthukumar Kannan; Ke Liao; Peter S Silverstein; Palsamy Periyasamy; Shilpa Buch
Journal:  Neurosci Lett       Date:  2021-03-29       Impact factor: 3.197

7.  Enhanced human immunodeficiency virus Type 1 expression and neuropathogenesis in knockout mice lacking Type I interferon responses.

Authors:  Hongxia He; Leroy R Sharer; Wei Chao; Chao-Jiang Gu; Alejandra Borjabad; Eran Hadas; Jennifer Kelschenbach; Koji Ichiyama; Meilan Do; Mary Jane Potash; David J Volsky
Journal:  J Neuropathol Exp Neurol       Date:  2014-01       Impact factor: 3.685

8.  Modeling HIV-1 Induced Neuroinflammation in Mice: Role of Platelets in Mediating Blood-Brain Barrier Dysfunction.

Authors:  Letitia D Jones; Joseph W Jackson; Sanjay B Maggirwar
Journal:  PLoS One       Date:  2016-03-17       Impact factor: 3.240

Review 9.  Targeting the glutamatergic system for the treatment of HIV-associated neurocognitive disorders.

Authors:  Michelle C Potter; Mariana Figuera-Losada; Camilo Rojas; Barbara S Slusher
Journal:  J Neuroimmune Pharmacol       Date:  2013-04-04       Impact factor: 4.147

10.  Proteomic modeling for HIV-1 infected microglia-astrocyte crosstalk.

Authors:  Tong Wang; Nan Gong; Jianuo Liu; Irena Kadiu; Stephanie D Kraft-Terry; R Lee Mosley; David J Volsky; Pawel Ciborowski; Howard E Gendelman
Journal:  PLoS One       Date:  2008-06-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.